3 out of 4 early stage hormone receptor-positive breast
cancer patients may not
benefit from chemotherapy.

First test to be validated on Indian patients

1000+ sample validation cohort

10+ validation partners in India, USA and Europe

20+ invited presentations in major international conferences

CAP accredited, ISO 13485 certified


Founded in 2011, OncoStem develops highly innovative multi-marker tests that identify patterns of recurrence amongst cancer patients. Our expertise in tumor biology assists physicians in developing optimal therapeutic plans for patients. We use the latest technology to facilitate personalized cancer treatment, improving quality of life for patients.

CanAssist Breast

CanAssist Breast is a prognostic test developed by OncoStem that classifies the patients as ‘low-risk’ or ‘high-risk’ based on the patient’s risk of breast cancer recurrence over five years. CanAssist Breast provides information about the risk of recurrence of early-stage, hormone receptor-positive breast cancer patients. This test analyses critical biomarkers in the tumor to assess the risk of recurrence, and helps oncologists to personalize treatment plans.